Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease

Human Molecular Genetics

Volumn 23, Issue 12, 2014, Pages 3129-3137

  Vittori, Angelica ^a,b   Breda, Carlo ^a   Repici, Mariaelena ^a   Orth, Michael ^c   Roos, Raymund A C ^d   Outeiro, Tiago F ^b,e,f   Giorgini, Flaviano ^a   Hollox, Edward J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF ULM   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LISBON   (Portugal)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; DROSOPHILA PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CAG REPEAT; COHORT ANALYSIS; COPY NUMBER VARIATION; DIPLOIDY; DROSOPHILA; DROSOPHILA MELANOGASTER; GENE OVEREXPRESSION; GENOTYPE; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; IMMUNOBLOTTING; LIFE EXPECTANCY; LIFESPAN; LOSS OF FUNCTION MUTATION; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; CELL LINE; DISEASE MODEL; FEMALE; GENE DOSAGE; GENETICS; HUNTINGTON DISEASE; MALE; METABOLISM; PATHOLOGY; PHYLOGENY; UPREGULATION;

AGE OF ONSET; ANIMALS; CELL LINE; COHORT STUDIES; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FEMALE; GENE DOSAGE; GLUCOSE TRANSPORTER TYPE 3; HUMANS; HUNTINGTON DISEASE; MALE; PHYLOGENY; UP-REGULATION;

EID: 84901308314     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu022     Document Type: Article

References (43)

1. Finkbeiner, S. (2011) Huntington's disease. Cold Spring Harb. Perspect. Biol., 3, a007476.
2. Roos, R.A. (2010) Huntington's disease: a clinical review. Orphanet J. Rare Dis., 5, 40.
3. Wexler, N.S. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA, 101, 3498-3503.
4. Mazziotta, J.C., Phelps, M.E., Pahl, J.J., Huang, S.-C., Baxter, L.R., Riege, W.H., Hoffman, J.M., Kuhl, D.E., Lanto, A.B. and Wapenski, J.A. (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med., 316, 357-362.
5. Antonini, A., Leenders, K., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., De Yebenez, J., Boesiger, P. and Weindl, A. (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain, 119, 2085-2095.
6. Ciarmiello, A., Cannella, M., Lastoria, S., Simonelli, M., Frati, L., Rubinsztein, D.C. and Squitieri, F. (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinicalsymptoms of Huntington's disease. J. Nucl. Med., 47, 215-222.
7. Grafton, S.T., Mazziotta, J.C., Pahl, J.J., George-Hyslop, P.S., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R. and Phelps, M.E. (1990) A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann. Neurol., 28, 614-621.
8. Hayden, M., Hewitt, J., Stoessl, A., Clark, C., Ammann, W. and Martin, W. (1987) The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology, 37, 1441-1447.
9. Kuhl, D.E., Phelps, M.E., Markham, C.H., Metter, E.J., Riege, W.H. and Winter, J. (1982) Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol., 12, 425-434.
10. Ciarmiello, A., Giovacchini, G., Orobello, S., Bruselli, L., Elifani, F. and Squitieri, F. (2012) 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur. J. Nucl. Med. Mol. Imaging, 39, 1030-1036.
11. Shin, H., Kim, M.H., Lee, S.J., Lee, K.-H., Kim, M.-J., Kim, J.S. and Cho, J.W. (2013) Decreased metabolism in the cerebral cortex in early-stage Huntington's disease: a possible biomarker of disease progression? J. Clin. Neurol., 9, 21-25.
12. Cepeda-Prado, E., Popp, S., Khan, U., Stefanov, D., Rodríguez, J., Menalled, L.B., Dow-Edwards, D., Small, S.A. and Moreno, H. (2012) R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J. Neurosci., 32, 6456-6467.
13. Li, X., Valencia, A., McClory, H., Sapp, E., Kegel, K.B. and DiFiglia, M. (2012) Deficient Rab11 activity underlies glucose hypometabolism in primary neurons of Huntington's disease mice. Biochem. Biophys. Res. Commun., 421, 727-730.
14. Besson, M.-T., Dupont, P., Fridell, Y.-W.C. and Liévens, J.-C. (2010) Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease. Hum. Mol. Genet., 19, 3372-3382.
15. Mueckler, M. and Thorens, B. (2013) The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med., 34, 121-138.
16. Simpson, I.A., Dwyer, D., Malide, D., Moley, K.H., Travis, A. and Vannucci, S.J. (2008) The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol. Endocrinol. Metab., 295, E242-E253.
17. Zhao, Y., Fung, C., Shin, D., Shin, B., Thamotharan, S., Sankar, R., Ehninger, D., Silva, A. and Devaskar, S. (2009) Neuronal glucose transporter isoform 3 deficient mice demonstrate features of autism spectrum disorders. Mol. Psychiatry, 15, 286-299.
18. Stuart, C.A., Ross, I.R., Howell, M.E., McCurry, M.P., Wood, T.G., Ceci, J.D., Kennel, S.J. and Wall, J. (2011) Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Res., 1384, 15-22.
19. Fung, C., Evans, E., Shin, D., Shin, B.C., Zhao, Y., Sankar, R., Chaudhuri, G. and Devaskar, S.U. (2010) Hypoxic-ischemic brain injury exacerbates neuronal apoptosis and precipitates spontaneous seizures in glucose transporter isoform 3 heterozygous null mice. J. Neurosci. Res., 88, 3386-3398.
20. Veal, C.D., Reekie, K.E., Lorentzen, J.C., Gregersen, P.K., Padyukov, L. and Brookes, A.J. (2014) A 129 kb deletion on chromosome 12 confers substantial protection against rheumatoid arthritis, implicating the gene SLC2A3. Hum. Mutat., 35, 248-256.
21. Fu, Y., Maianu, L., Melbert, B.R. and Garvey, W.T. (2004) Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol. Dis., 32, 182-190.
22. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O.,Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 97, 6763-6768.
23. Campesan, S., Green, E.W., Breda, C., Sathyasaikumar, K.V., Muchowski, P.J., Schwarcz, R., Kyriacou, C.P. and Giorgini, F. (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol., 21, 961-966.
24. Green, E.W., Campesan, S., Breda, C., Sathyasaikumar, K.V., Muchowski, P.J., Schwarcz, R., Kyriacou, C.P. and Giorgini, F. (2012) Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly (Austin), 6, 117-120.
25. Mason, R.P., Casu, M., Butler, N., Breda, C., Campesan, S., Clapp, J., Green, E.W., Dhulkhed, D., Kyriacou, C.P. and Giorgini, F. (2013) Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat. Genet., 45, 1249-1254.
26. Richards, P., Didszun, C., Campesan, S., Simpson, A., Horley, B., Young, K.W., Glynn, P., Cain, K., Kyriacou, C.P., Giorgini, F. et al. (2011) Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ., 18, 191-200.
27. Sajjad, M.U., Green, E.W., Miller-Fleming, L., Hands, S., Herrera, F., Campesan, S., Khoshnan, A., Outeiro, T.F., Giorgini, F. and Wyttenbach, A. (2014) DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease. Hum. Mol. Genet., 23, 755-766.
28. Steinert, J.R., Campesan, S., Richards, P., Kyriacou, C.P., Forsythe, I.D. and Giorgini, F. (2012) Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease. Hum. Mol. Genet., 21, 2912-2922.
29. Shulman, J.M., Chipendo, P., Chibnik, L.B., Aubin, C., Tran, D., Keenan, B.T., Kramer, P.L., Schneider, J.A., Bennett, D.A., Feany, M.B. et al. (2011) Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am. J. Hum. Genet., 88, 232-238.
30. Singleton, A., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A. and Nussbaum, R. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
31. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
32. Gusella, J.F. and MacDonald, M.E. (2009) Huntington's disease: the case for genetic modifiers. Genome Med., 1, 80.
33. Lee, J.-H., Lee, J.-M., Ramos, E.M., Gillis, T., Mysore, J.S., Kishikawa, S., Hadzi, T., Hendricks, A.E., Hayden, M.R. and Morrison, P.J. (2012) TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem. Biophys. Res. Commun., 424, 404-408.
34. Ramos, E.M., Latourelle, J.C., Lee, J.-H., Gillis, T., Mysore, J.S., Squitieri, F., Di Pardo, A., Di Donato, S., Hayden, M.R. and Morrison, P.J. (2012) Population stratification may bias analysis of PGC-1a as a modifier of age at Huntington disease motor onset. Hum. Genet., 131, 1833-1840.
35. Gamberino, W. and Brennan,W. (1994) Glucose transporter isoform expression in Huntington's disease brain. J. Neurochem., 63, 1392-1397.
36. Orth, M., Handley, O., Schwenke, C., Dunnett, S., Craufurd, D., Ho, A., Wild, E., Tabrizi, S. and Landwehrmeyer, G. and Network", I.o.t.E.H.s.D. (2010) Observing Huntington's disease: the European Huntington's disease Network's REGISTRY. PLoS Curr. Edition 1. doi:10.1371/ currents.RRN1184.
37. Huntington Study Group (1996) Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord., 11, 136-142.
38. Armour, J.A.L., Palla, R., Zeeuwen, P.L.J.M., den Heijer, M., Schalkwijk, J. and Hollox, E.J. (2007) Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats. Nucleic Acids Res., 35, e19.
39. Reekie, K.E. (2011) Technological and Biological Studies of Human Structural Variation. PhD thesis, Department of Genetics, University of Leicester.
40. Bonny, C., Oberson, A., Negri, S., Sauser, C. and Schorderet, D.F. (2001) Cell-permeable peptide inhibitors of JNK novel blockers of b-cell death. Diabetes, 50, 77-82.
41. Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M. and Kumar, S. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol., 28, 2731-2739.
42. Jones, D.T., Taylor, W.R. and Thornton, J.M. (1992) The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci., 8, 275-282.
43. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z. and Greenwald, M. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739-743.